The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1362
Eribulin Mesylate (Halaven) for Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Eribulin mesylate (Halaven – Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer. Prior therapy should have included an anthracycline and a taxane in either an adjuvant or metastatic setting. Other drugs used to treat anthracycline- and taxane-refractory metastatic breast cancer include capecitabine (Xeloda), gemcitabine (Gemzar, and others) and vinorelbine (Navelbine, and others).1

MECHANISM OF ACTION — Eribulin is an analog of halichondrin B, a macrolide found in marine sponges that has marked anticancer activity. It suppresses microtubule polymerization and sequesters tubulin into nonfunctional aggregates.2

CLINICAL STUDIES — Approval of eribulin was ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Eribulin Mesylate (Halaven) for Breast Cancer
Article code: 1362c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian